Walleye Capital’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Walleye Capital’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-117,704	Closed	-$1.19M	–	4651
2022 Q4	$1.19M	Hold	117,704	–	–	0.02%	890
2022 Q3	$1.17M	Hold	117,704	–	–	0.02%	862
2022 Q2	$1.17M	Buy	117,704 +35,907	+44%	+$352K	0.03%	571
2022 Q1	$807K	Sell	81,797 -12,692	-13%	-$125K	0.02%	740
2021 Q4	$930K	Buy	+94,489	New	+$928K	0.03%	639

Walleye Capital's BIOT Position: Q1 2023 in Review

Walleye Capital sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 117,704 shares — an estimated $1.19M sold.

Walleye Capital first reported a position in BIOT in Q4 2021 and held it in 5 quarters. The position peaked at $1.19M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Walleye Capital reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Walleye Capital sold 117,704 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $1.19M.
Walleye Capital first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2021 and held it in 5 quarters.
Walleye Capital's Biotech Acquisition Company Class A Ordinary Shares position peaked at $1.19M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Walleye Capital's 13F filing for Q1 2023, filed 15 May 2023.